Safety and efficacy of target-controlled infusion of remazolam and its interaction with other narcotic drugs

Clinical observation of the interaction between remazolam and other anesthetic drugs

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400084302

Enrollment

Unknown

Registered

2024-05-14

Start date

2024-05-15

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NONE

Interventions

Observation group 1 (Target controlled infusion remazola and propofol):NA

Observation group 2 (Target controlled infusion remazola and sufentanil):NA

Observation group 3 (Target controlled infusion remazola and remifentanil):NA

Observation group 4 (Target controlled infusion remazola and esketamine):NA

Observation group 5 (Target controlled infusion remazola and dexmedetomidine):NA

Eligibility

Sex/Gender

All

Age

25 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: American Society of Anesthesiologists (ASA) Level I ~ II; Patients aged 25-55 years old, both male and female; BMI: 18.5~24.0kg/m^2, height: 155~175cm, weight > 50kg;

Exclusion criteria

Exclusion criteria: Allergic to benzodiazepines; Pre-existing respiratory or cardiovascular disease; Long-term use of sedatives and analgesics, history of drug use.

Design outcomes

Primary

Measure	Time frame
BIS;blood pressure;	—

Secondary

Measure	Time frame
Nausea and vomiting;HR;RR;SP02;	—

Countries

China

Contacts

Public ContactWang Tianhai

Affiliated Cancer Hospital of Xinjiang Medical University

1554906530@qq.com+86 135 7988 3521

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026